Exciting Development in Thyroid Cancer Treatment: The Clinical Trial Vanguard Features Executive Interview on Innovative Thyroid Cancer Tests. Special thanks to Moe Alsumidaie and The Clinical Trial Vanguard for sharing…
![Read more about the article A clinically useful and biologically informative genomic classifier for papillary thyroid cancer [2023]](https://qualisuredx.com/wp-content/uploads/2023/09/Graphical-Abstract-small.jpg)
Front. Endocrinol., 12 September 2023Sec. Thyroid EndocrinologyVolume 14 - 2023 Clinical management of papillary thyroid cancer depends on estimations of prognosis. Standard care, which relies on prognostication based on clinicopathologic…
See the full Made in CA Interview with Dr. Oliver Bathe MD, FRCSC, FACS
Listen to our CEO, Dr. Oliver Bathe talk about Qualisure's innovation and the work he's done to transition from being a medical practitioner to a full-time entrepreneur. https://www.buzzsprout.com/766547/12261737
October 19-23 2022. Dr. Oliver Bathe presented results from a study of 742 patients at the 2022 Annual Meeting of the American Thyroid Association. The study demonstrated that Thyroid GuidePx®…
CALGARY, ALBERTA, Recently Jon Hagan, Senior Business Partner in Marketing and Communications at Alberta Innovates, sat down with our CEO Dr. Oliver Bathe. Jon explored the Qualisure commercialization journey with…
Qualisure Diagnostics is pleased to announce the launch of our first diagnostic test, Thyroid GuidePx® for papillary thyroid cancer, the most common type of thyroid cancer. Thyroid GuidePx® is the…
Dr. Cynthia Stretch (Chief Scientific Officer) presented details on the molecular features of molecular subgroups of papillary thyroid cancer that are identifiable using Thyroid GuidePx™ at the Annual Meeting of…
Sign up to receive updates from Qualisure regarding our latest developments in precision medicine tools.
